What is Lexaria Bioscience Earnings Yield (Joel Greenblatt) %?
Lexaria Bioscience's Enterprise Value for the quarter that ended in Feb. 2024 was $37.72 Mil.
Lexaria Bioscience's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-5.25 Mil. Lexaria Bioscience's Earnings Yield (Joel Greenblatt) for the quarter that ended in Feb. 2024 was -13.91%.
The historical rank and industry rank for Lexaria Bioscience's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
LEXX'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1000.03 Med: -20.11 Max: 10.69
Current: -19.38
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Lexaria Bioscience was 10.69%. The lowest was -1000.03%. And the median was -20.11%.
LEXX's Earnings Yield (Joel Greenblatt) % is ranked worse than 55.6% of 1394
companies
in the Biotechnology industry
Industry Median: -15.435
vs LEXX: -19.38
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Lexaria Bioscience's Forward Rate of Return (Yacktman) % for the quarter that ended in Feb. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Lexaria Bioscience Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Lexaria Bioscience's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lexaria Bioscience's Earnings Yield (Joel Greenblatt) %
For the Biotechnology subindustry, Lexaria Bioscience's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Lexaria Biosciences Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Aug. 2023 is calculated as
Lexaria Bioscience's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.25 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Lexaria Bioscience Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Lexaria Bioscience's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexaria Bioscience (Lexaria Bioscience) Business Description
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LEXX has been successfully added to your 